Gespeichert in:
| Beteiligte Personen: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
[Washington, D.C]
World Bank
2005
|
| Schriftenreihe: | Policy research working paper
3670 |
| Schlagwörter: | |
| Links: | https://hdl.handle.net/10986/8195 |
| Beschreibung: | Includes bibliographical references. - Title from PDF file as viewed on 8/16/2005 Erscheinungsjahr in Vorlageform:[2005] |
| Umfang: | 1 Online-Ressource (28 Seiten) |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV040618275 | ||
| 003 | DE-604 | ||
| 005 | 20250311 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 121206s2005 xxu o|||| 00||| eng d | ||
| 035 | |a (ZDB-1-WBA)09322222X | ||
| 035 | |a (OCoLC)874233563 | ||
| 035 | |a (DE-599)GBVNLM005458374 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-12 |a DE-1102 |a DE-1051 |a DE-521 |a DE-863 |a DE-862 |a DE-522 |a DE-858 |a DE-573 |a DE-860 |a DE-1046 |a DE-1047 |a DE-Aug4 |a DE-2070s |a DE-M347 |a DE-1049 |a DE-898 |a DE-128 |a DE-M352 |a DE-70 |a DE-92 |a DE-150 |a DE-155 |a DE-22 |a DE-91 |a DE-384 |a DE-473 |a DE-19 |a DE-739 |a DE-20 |a DE-703 |a DE-706 |a DE-355 |a DE-29 |a DE-859 |a DE-Re13 |a DE-523 | ||
| 050 | 0 | |a HG3881.5.W57 | |
| 100 | 1 | |a Laxminarayan, Ramanan |e Verfasser |0 (DE-588)17189264X |4 aut | |
| 245 | 1 | 0 | |a Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |c Ramanan Laxminarayan, Mead Over, David L. Smith |
| 264 | 1 | |a [Washington, D.C] |b World Bank |c 2005 | |
| 300 | |a 1 Online-Ressource (28 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Policy research working paper |v 3670 | |
| 500 | |a Includes bibliographical references. - Title from PDF file as viewed on 8/16/2005 | ||
| 500 | |a Erscheinungsjahr in Vorlageform:[2005] | ||
| 520 | 1 | |a "Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With rapidly increasing parasite resistance to chloroquine in many parts of the world, there is greater international recognition of the need for both a different antimalarial and a coordinated malaria treatment strategy to ensure that resistance does not needlessly cut short the useful therapeutic life of any successor drug to chloroquine. The effectiveness of antimalarial drugs is a global public good, of particular value in malarious regions that also are among the most economically impoverished parts of the world. Inappropriate drug use in neighboring countries reduces the incentive of any given country to deploy drug regimens that may be rapidly undermined by resistance originating outside their borders. Therefore, a case can be made for globally coordinated action to protect the effectiveness of these valuable drugs. Translating this case to one for a global subsidy is not straightforward. On the one hand, in the absence of such a subsidy to ensure that ACTs are comparably priced to monotherapies, increasing monotherapy of artemisinin and other antimalarials that would be used along with artemisinin in ACT will hasten the demise of this drug. On the other hand, a global subsidy would greatly increase the use and potential misuse of ACTs and could result in resistance emerging at a more rapid rate. This study finds that a subsidy to ACTs is likely to slow the rate of emergence of resistance to artemisinin and partner drugs, even if such a subsidy were to increase the use of ACTs significantly. This conclusion is robust to alternative assumptions regarding the responsiveness of demand to the lower price for ACTs and a wide range of epidemiological and economic parameters. | |
| 520 | 1 | |a [Fortsetzung 1. Abstract] However, the simulation results show that a subsidy for two or more ACT combinations is likely to be much more cost-effective than a subsidy to a single ACT. The only consideration is that the drugs used as partners to artemisinin be unrelated to each other and to artemisinin in mechanism of action and in genetic bases of resistance, so that a single mutation cannot encode resistance to both components. Such a subsidy program for ACTs, administered globally, that reduces reliance on any single combination, and discourages monotherapy, not only of artemisinin but of any effective antimalarial that could potentially be used as partner drug with artemisinin, is likely to be effective (and cost-effective) both in buying time for ACTs and in saving lives "--World Bank web site | |
| 534 | |c 2005 | ||
| 653 | |a Artemisinin | ||
| 653 | |a Artemisinin |a Economic aspects | ||
| 653 | |a Malaria |a Treatment | ||
| 700 | 1 | |a Over, A. Mead |e Verfasser |4 aut | |
| 710 | 2 | |a World Bank |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Reproduktion von |a Laxminarayan, Ramanan |t Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |d 2005 |
| 856 | 4 | 0 | |u https://hdl.handle.net/10986/8195 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-1-WBA | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-025445774 | |
Datensatz im Suchindex
| DE-BY-OTHR_katkey | 5051517 |
|---|---|
| DE-BY-TUM_katkey | 1900691 |
| DE-BY-UBR_katkey | 5051517 |
| _version_ | 1835111751384825856 |
| adam_text | |
| any_adam_object | |
| author | Laxminarayan, Ramanan Over, A. Mead |
| author_GND | (DE-588)17189264X |
| author_facet | Laxminarayan, Ramanan Over, A. Mead |
| author_role | aut aut |
| author_sort | Laxminarayan, Ramanan |
| author_variant | r l rl a m o am amo |
| building | Verbundindex |
| bvnumber | BV040618275 |
| callnumber-first | H - Social Science |
| callnumber-label | HG3881 |
| callnumber-raw | HG3881.5.W57 |
| callnumber-search | HG3881.5.W57 |
| callnumber-sort | HG 43881.5 W57 |
| callnumber-subject | HG - Finance |
| collection | ZDB-1-WBA |
| ctrlnum | (ZDB-1-WBA)09322222X (OCoLC)874233563 (DE-599)GBVNLM005458374 |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV040618275</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20250311</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">121206s2005 xxu o|||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-1-WBA)09322222X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)874233563</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVNLM005458374</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield><subfield code="a">DE-522</subfield><subfield code="a">DE-858</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield><subfield code="a">DE-Aug4</subfield><subfield code="a">DE-2070s</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-128</subfield><subfield code="a">DE-M352</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-150</subfield><subfield code="a">DE-155</subfield><subfield code="a">DE-22</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-523</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HG3881.5.W57</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Laxminarayan, Ramanan</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)17189264X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives?</subfield><subfield code="c">Ramanan Laxminarayan, Mead Over, David L. Smith</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Washington, D.C]</subfield><subfield code="b">World Bank</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (28 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Policy research working paper</subfield><subfield code="v">3670</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references. - Title from PDF file as viewed on 8/16/2005</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Erscheinungsjahr in Vorlageform:[2005]</subfield></datafield><datafield tag="520" ind1="1" ind2=" "><subfield code="a">"Artemisinin-based combination treatments (ACTs) are seen as an important tool in the global effort to roll back malaria. With rapidly increasing parasite resistance to chloroquine in many parts of the world, there is greater international recognition of the need for both a different antimalarial and a coordinated malaria treatment strategy to ensure that resistance does not needlessly cut short the useful therapeutic life of any successor drug to chloroquine. The effectiveness of antimalarial drugs is a global public good, of particular value in malarious regions that also are among the most economically impoverished parts of the world. Inappropriate drug use in neighboring countries reduces the incentive of any given country to deploy drug regimens that may be rapidly undermined by resistance originating outside their borders. Therefore, a case can be made for globally coordinated action to protect the effectiveness of these valuable drugs. Translating this case to one for a global subsidy is not straightforward. On the one hand, in the absence of such a subsidy to ensure that ACTs are comparably priced to monotherapies, increasing monotherapy of artemisinin and other antimalarials that would be used along with artemisinin in ACT will hasten the demise of this drug. On the other hand, a global subsidy would greatly increase the use and potential misuse of ACTs and could result in resistance emerging at a more rapid rate. This study finds that a subsidy to ACTs is likely to slow the rate of emergence of resistance to artemisinin and partner drugs, even if such a subsidy were to increase the use of ACTs significantly. This conclusion is robust to alternative assumptions regarding the responsiveness of demand to the lower price for ACTs and a wide range of epidemiological and economic parameters.</subfield></datafield><datafield tag="520" ind1="1" ind2=" "><subfield code="a">[Fortsetzung 1. Abstract] However, the simulation results show that a subsidy for two or more ACT combinations is likely to be much more cost-effective than a subsidy to a single ACT. The only consideration is that the drugs used as partners to artemisinin be unrelated to each other and to artemisinin in mechanism of action and in genetic bases of resistance, so that a single mutation cannot encode resistance to both components. Such a subsidy program for ACTs, administered globally, that reduces reliance on any single combination, and discourages monotherapy, not only of artemisinin but of any effective antimalarial that could potentially be used as partner drug with artemisinin, is likely to be effective (and cost-effective) both in buying time for ACTs and in saving lives "--World Bank web site</subfield></datafield><datafield tag="534" ind1=" " ind2=" "><subfield code="c">2005</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Artemisinin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Artemisinin</subfield><subfield code="a">Economic aspects</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Malaria</subfield><subfield code="a">Treatment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Over, A. Mead</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">World Bank</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Reproduktion von</subfield><subfield code="a">Laxminarayan, Ramanan</subfield><subfield code="t">Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives?</subfield><subfield code="d">2005</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://hdl.handle.net/10986/8195</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-WBA</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025445774</subfield></datafield></record></collection> |
| id | DE-604.BV040618275 |
| illustrated | Not Illustrated |
| indexdate | 2025-03-11T17:03:46Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025445774 |
| oclc_num | 874233563 |
| open_access_boolean | 1 |
| owner | DE-12 DE-1102 DE-1051 DE-521 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-522 DE-858 DE-573 DE-860 DE-1046 DE-1047 DE-Aug4 DE-2070s DE-M347 DE-1049 DE-898 DE-BY-UBR DE-128 DE-M352 DE-70 DE-92 DE-150 DE-155 DE-BY-UBR DE-22 DE-BY-UBG DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-739 DE-20 DE-703 DE-706 DE-355 DE-BY-UBR DE-29 DE-859 DE-Re13 DE-BY-UBR DE-523 |
| owner_facet | DE-12 DE-1102 DE-1051 DE-521 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-522 DE-858 DE-573 DE-860 DE-1046 DE-1047 DE-Aug4 DE-2070s DE-M347 DE-1049 DE-898 DE-BY-UBR DE-128 DE-M352 DE-70 DE-92 DE-150 DE-155 DE-BY-UBR DE-22 DE-BY-UBG DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-739 DE-20 DE-703 DE-706 DE-355 DE-BY-UBR DE-29 DE-859 DE-Re13 DE-BY-UBR DE-523 |
| physical | 1 Online-Ressource (28 Seiten) |
| psigel | ZDB-1-WBA |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | World Bank |
| record_format | marc |
| series2 | Policy research working paper |
| spellingShingle | Laxminarayan, Ramanan Over, A. Mead Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |
| title | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |
| title_auth | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |
| title_exact_search | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |
| title_full | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? Ramanan Laxminarayan, Mead Over, David L. Smith |
| title_fullStr | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? Ramanan Laxminarayan, Mead Over, David L. Smith |
| title_full_unstemmed | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? Ramanan Laxminarayan, Mead Over, David L. Smith |
| title_short | Will a global subsidy of artemisinin-based combination treatment (act) for malaria delay the emergence of resistance and save lives? |
| title_sort | will a global subsidy of artemisinin based combination treatment act for malaria delay the emergence of resistance and save lives |
| url | https://hdl.handle.net/10986/8195 |
| work_keys_str_mv | AT laxminarayanramanan willaglobalsubsidyofartemisininbasedcombinationtreatmentactformalariadelaytheemergenceofresistanceandsavelives AT overamead willaglobalsubsidyofartemisininbasedcombinationtreatmentactformalariadelaytheemergenceofresistanceandsavelives AT worldbank willaglobalsubsidyofartemisininbasedcombinationtreatmentactformalariadelaytheemergenceofresistanceandsavelives |